The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes an...
Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.
No comments yet
Be the first to share your thoughts!